W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

Transparency Council

21 August, 2024

Position of the Transparency Council – Brukinsa (zanubrutinib)

21 August, 2024

Position of the Transparency Council – cytology on liquid medium

21 August, 2024

Communication of the meeting of Transparency Council No. 35/2024 on 19 August 2024

16 August, 2024

Communication of the meeting of Transparency Council No. 34/2024 on 12 August 2024

13 August, 2024

The Transparency Council meeting 35/2024 on 19 August 2024

08 August, 2024

Communication of the meeting of Transparency Council No. 33/2024 on 5 August 2024

08 August, 2024

The Transparency Council meeting 34/2024 on 12 August 2024

01 August, 2024

Communication of the meeting of Transparency Council No. 32/2024 on 29 July 2024

30 July, 2024

The Transparency Council meeting 33/2024 on 5 August 2024

25 July, 2024

Communication of the meeting of Transparency Council No. 31/2024 on 22 July 2024

24 July, 2024

The Transparency Council meeting 32/2024 on 29 July 2024

17 July, 2024

The Transparency Council meeting 31/2024 on 22 July 2024

10 July, 2024

Communication of the meeting of Transparency Council No. 29/2024 on 8 July 2024

10 July, 2024

The Transparency Council meeting 30/2024 on 15 July 2024

02 July, 2024

The Transparency Council meeting on 8 July 2024

27 June, 2024

The Transparency Council meeting 28/2024 on 1 July 2024

27 June, 2024

Communication of the meeting of Transparency Council No. 27/2024 on 24 June 2024

20 June, 2024

Communication of the meeting of Transparency Council No. 26/2024

23 May, 2023

Opinion of the Transparency Council – dexamethasone

23 May, 2023

Opinion of the Transparency Council – amendments to part B of the drug programme B.70

23 May, 2023

Opinion of the Transparency Council – health policy programme of the City of Białystok

23 May, 2023

Opinion of the Transparency Council – health policy programme of the City of Zduńska Wola

23 May, 2023

Position of the Transparency Council – Adtralza (tralokinumab)

22 May, 2023

Meeting of the Transparency Council 20/2023 on 22 May 2023 – Update

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑